AlphAIAlphAI — Financial news for AI agents
investing.com$PIII

P3 Health Partners earnings beat by $4.86, revenue topped estimates

P3 Health Partners (PIII) reported Q3 EPS of $0.07, beating estimates by $4.86, with revenue of $396.34M, exceeding expectations. The company forecasts FY 2026 revenue between $1.53B-$1.6B. The stock is down 61.2% over the last 3 months and 43.33% over the past year.

Original reporting
investing.com
Published Nov 9, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PIII
Bullish
high confidence
Mentioned
$PIII
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PIIIBullishMed
01

Why it matters

Earnings beat provides fresh data for traders to reassess valuation.

02

Market read

First‑report earnings data for a micro‑cap health services firm, offering a modest trading opportunity.

03

What to watch

Guidance is roughly in line with consensus, limiting upside potential.

Relevance 7/10Novelty 8/10Timing: post-market

Background

P3 Health Partners is a small‑cap healthcare services company listed on NASDAQ.

Company-level read

Ticker impact

$PIIIBullishHigh confidence
Context

P3 Health Partners reported Q3 EPS of $0.07 beating estimates by $4.86 and revenue of $396.34M above consensus.

Expected impact

potential upside as market prices in the earnings beat

Evidence & confidence

Beat on both EPS and revenue suggests better-than-expected performance, likely prompting investors to add positions.

Market effects

Sector

May lift sentiment in the healthcare services sector.

Regional

Limited to U.S. small‑cap investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The beat could be priced in quickly, leading to a short‑term pullback.

Key entities

  • company
    P3 Health Partners

    NASDAQ‑listed healthcare services firm.

Read at source← All news

StoryP3 Health Partners posts Q3 profit, lifts 2026 adjusted EBITDA outlook

Also covered by

2 outlets

Related articles

$PIIIMed

P3 Health (PIII) Q3 2026 Earnings Call Transcript

P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.

finance.yahoo.com
$PIIIMed

P3 Health Partners Announces Third Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Third Quarter 2026 Results Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint Management to Host Conference Call and Webcast November 9, 2026 at 4:30

SEC EDGAR 8-K
$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.

fool.com
$PIIIHigh

P3 Health Partners Announces Second Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:

SEC EDGAR 8-K